BRIM 3: A randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients with Unresectable Stage IIIC Stage IV Melanoma
Laufzeit: 01.01.2010 - 31.12.2012
imported
Kurzfassung
A randomized, open-label, multi-center, active treatment controlled, Phase III trial that will evaluate the efficacy and safety of RO5185426 compared to dacarbazine in previously untreated patients with histologically confirmed metastatic melanoma ( unresectable Stage IIIC or stage iV) harboring the BRAF V600E mutation
